ELAPRASE

ApprovedProtein / enzyme

Takeda

ELAPRASE is one of 73 small molecule programs targeting Cognitive impairment. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

MucopolysaccharidosisActive, not recruiting

Cognitive ImpairmentPhase 1/Phase 2

Active, not recruiting

MucopolysaccharidosisApproved

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

3 2

Farxiga

AstraZeneca

Phase 3

1 3

Provigil

NNuvo Research GmbH

Phase 3

1 4

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 5

Xarelto

WWim Janssens

Phase 3

1 6

Viagra

VViatris Specialty LLC

Phase 3

1 7

Donepezil Hydrochloride

Eisai

Phase 3

3 8

Statins

Sanofi

Phase 3

1 9

Galantamine Hydrobromide

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

4 10

Karxt

Bristol-Myers Squibb

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2/3Active, not recruiting

Cognitive Impairment

NCT06031259

Clinical

Trials by Indication[1]

Mucopolysaccharidosis2 trials

A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Withdrawn· Takeda logo

Takeda·Phase 4·NCT05494593

A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

Completed· Takeda logo

Takeda·Phase 4·NCT05058391·5 enrolled

Cognitive impairment2 trials

Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

Active, not recruiting· Takeda logo

Takeda·Phase 2/3·NCT06031259·6 enrolled

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

Completed· Takeda logo

Takeda·Phase 1/2·NCT01506141·15 enrolled

Treatment1 trial

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

Completed· Takeda logo

Takeda·Phase 2/3·NCT02412787·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ELAPRASE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ELAPRASE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ELAPRASE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Approved[1]
Company: Takeda

ELAPRASE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Mucopolysaccharidosis2 trials

Cognitive impairment2 trials

Treatment1 trial

References

Drug Info

Quick Facts

Related News